Rifapentine
- Generic Name
- Rifapentine
- Brand Names
- Priftin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H64N4O12
- CAS Number
- 61379-65-5
- Unique Ingredient Identifier
- XJM390A33U
- Background
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
- Indication
For the treatment of pulmonary tuberculosis.
- Associated Conditions
- Active Tuberculosis, Late phase Tuberculosis
Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis
- Conditions
- Infertility, FemaleRecurrent Implantation FailureGenital Tuberculoses, FemaleGenital Tuberculosis, Latent
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 1050
- Registration Number
- NCT04528277
- Locations
- 🇨🇳
Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China
Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
- Conditions
- HIVTuberculosis
- Interventions
- Dietary Supplement: Pyridoxine (vitamin B6)
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 104
- Registration Number
- NCT04311502
- Locations
- 🇭🇹
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti
🇿🇼Milton Park CRS, Harare, Zimbabwe
🇿🇦CAPRISA eThekwini CRS, Durban, Kwa Zulu Natal, South Africa
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
- Conditions
- HIV InfectionLTBI
- Interventions
- Drug: Antiretroviral Therapy (ART)Dietary Supplement: Pyridoxine (Vitamin B6)
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 37
- Registration Number
- NCT04272242
- Locations
- 🇿🇦
University of Cape Town Lung Institute (UCTLI) CRS, Cape Town, South Africa
🇺🇸University of California HIV/AIDS CRS, San Francisco, California, United States
🇺🇸Houston AIDS Research Team CRS, Houston, Texas, United States
Doravirine, Rifapentine and Isoniazid Interaction
- Conditions
- Rifamycins Causing Adverse Effects in Therapeutic UseDrug Interaction PotentiationLatent TuberculosisHuman Immunodeficiency Virus
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Walter K. Kraft
- Target Recruit Count
- 11
- Registration Number
- NCT03886701
- Locations
- 🇺🇸
Thomas Jefferson University Clinical Research Unit, Philadelphia, Pennsylvania, United States
Video Based Directly Observed Therapy for Latent TB
- Conditions
- Latent Tuberculosis
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- St. Louis University
- Registration Number
- NCT03783728
- Locations
- 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
Tuberculosis Clinical Trials Consortium Study 35
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 72
- Registration Number
- NCT03730181
- Locations
- 🇿🇦
Desmond Tutu TB Center, University of Stellenbosch, Stellenbosch, South Africa
Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-08-13
- Target Recruit Count
- 51
- Registration Number
- NCT03510468
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- Conditions
- Latent Tuberculosis
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 3400
- Registration Number
- NCT03474029
- Locations
- 🇦🇺
Liverpool Hospital, Sydney, Australia
🇺🇸George Washington University, Washington, District of Columbia, United States
🇺🇸New York City Bureau of TB Control, New York, New York, United States
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University College, London
- Target Recruit Count
- 675
- Registration Number
- NCT03474198
- Locations
- 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬Infectious Diseases Institute, Kampala, Uganda
Treatment of Latent Tuberculosis in Socially Marginalised Citizens
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT03266991
- Locations
- 🇩🇰
Dept of Pulmonary Medicine, Esbjerg, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.